Key result
AVANT GUARD tests first-line pulsed field ablation versus antiarrhythmic drugs in persistent AF.
Why the study?
A critical gap exists in understanding treatment approaches and disease progression for patients with persistent AF.
Does pulsed field ablation improve treatment success compared to antiarrhythmic drug therapy as a first-line treatment in patients with persistent atrial fibrillation?
RCT
Randomized
Yes
Does pulsed field ablation improve treatment success compared to antiarrhythmic drug therapy as a first-line treatment in patients with persistent atrial fibrillation?
The AVANT GUARD trial is designed to evaluate whether pulsed field ablation is a safe and effective first-line alternative to antiarrhythmic drugs for patients with persistent atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Provides the first randomized framework comparing first-line pulsed field ablation against antiarr.
Background: Recent studies have established catheter ablation as a safe and superior alternative to antiarrhythmic drugs (AADs) as a first-line therapy in patients with paroxysmal atrial fibrillation (AF). There are no randomized controlled trials assessing this strategy in patients with persistent AF. Objective: This study aims to establish the safety and effectiveness of pulsed field ablation (PFA) as a first-line treatment for persistent AF compared with AAD therapy. Methods: AVANT GUARD (A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation vs Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation) is a multicenter, global, pivotal investigational device exemption study that compares the safety and effectiveness of PFA with the pentaspline PFA catheter to AADs as first-line therapy for patients with persistent AF. All patients will receive an implantable cardiac monitor. Results: The primary safety end point, evaluated in PFA subjects, is a composite of defined acute and chronic device- and procedure-related serious adverse events. The primary effectiveness end point, evaluated in randomized PFA and AAD subjects at 12-month follow-up, is a composite of acute and chronic treatment success including freedom from atrial arrhythmia recurrence lasting ≥30 seconds (symptomatic) or ≥1 hour (asymptomatic), electrical cardioversion, or (re)ablation. Conclusion: AVANT GUARD will help fill a critical gap in our understanding of treatment approaches and disease progression for patients with persistent AF by providing a direct comparison between ablation using PFA versus AAD treatment as a first-line therapy with continuous monitoring to assess outcomes.
No takes yet. Share an insight, caveat, or question.
WAZNI et al. (2025) conducted an RCT in Persistent atrial fibrillation. Pulsed field ablation vs. Antiarrhythmic drug therapy was evaluated on Composite of acute and chronic treatment success including freedom from atrial arrhythmia recurrence lasting ≥30 seconds (symptomatic) or ≥1 hour (asymptomatic), electrical cardioversion, or (re)ablation. The AVANT GUARD trial is designed to evaluate the safety and effectiveness of pulsed field ablation versus antiarrhythmic drugs as a first-line treatment for persistent atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: